Arcutis Biotherapeutics, Inc.
3 drugs in NADAC|0 Generic,3 Brand
Arcutis Biotherapeutics, Inc. lists 3 NDCs in the CMS NADAC file (0 generic, 3 brand), at an average NADAC of $15.39 per unit, with a week-over-week move of +0.0% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
3
0G / 3B
Avg Price / Unit
$15.3868
$15.38 – $15.40
Avg 7d Change
+0.02%
Across 2 drugs with changes
7d Activity
of 3 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
roflumilast market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Phosphodiesterase 4 Inhibitor therapeutic class
Review the broader class where Arcutis Biotherapeutics, Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Arcutis Biotherapeutics, Inc. make?
Arcutis Biotherapeutics, Inc. lists 3 NDCs in the CMS NADAC file — 0 generic and 3 brand products.
What is the average price of Arcutis Biotherapeutics, Inc. drugs?
The average NADAC across Arcutis Biotherapeutics, Inc.'s portfolio is $15.3868 per unit, ranging from $15.3778 to $15.3988.
What types of drugs does Arcutis Biotherapeutics, Inc. make?
Arcutis Biotherapeutics, Inc. makes drugs across 1 FDA pharmacologic class. The most common by NDC count are Phosphodiesterase 4 Inhibitor (3).
Has Arcutis Biotherapeutics, Inc. had any drug recalls?
No FDA enforcement recalls are matched to Arcutis Biotherapeutics, Inc. in the openFDA feed.
How has Arcutis Biotherapeutics, Inc.'s pricing changed recently?
Over the past 7 days, 2 Arcutis Biotherapeutics, Inc. products rose and 0 fell, with a portfolio-wide average change of +0.0%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
ZORYVE 0.15% CREAM roflumilast | $15.3987 per GM | +0.01% |
ZORYVE 0.3% CREAM roflumilast | $15.3839 per GM | +0.03% |
ZORYVE 0.3% FOAM roflumilast | $15.3778 per GM | 0.00% |